Dr. Faderl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3170 Porter Drive
Palo Alto, CA 94304- Is this information wrong?
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Steward Carney HospitalResidency, Internal Medicine, 1993 - 1996
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1990
Certifications & Licensure
TX State Medical License 1999 - 2025
NJ State Medical License 2013 - 2017- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Start of enrollment: 2001 Sep 06
- Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Start of enrollment: 2003 Jun 23
- Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) Start of enrollment: 2003 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsEfficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: pos...Jorge E Cortes, Tara L Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E Lancet, Thomas Prebet> ;Journal of Hematology & Oncology. 2022 Oct 26
- 6 citationsQuality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AMLJorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet> ;Journal of Hematology & Oncology. 2021 Jul 13
- 71 citationsCPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a ra...Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Dale L. B...> ;The Lancet. Haematology. 2021 Jul 1
- Join now to see all
Abstracts/Posters
- Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
John Theurer Cancer Center (JTCC) Researchers to Present 52 Abstracts Across Hematological Malignancies at the 2020 American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 4th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
